Lee Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,618
| Closed | -$165K | – | 864 |
|
|
2023
Q2 | $165K | Hold |
1,618
| – | – | 0.03% | 138 |
|
|
2023
Q1 | $147K | Hold |
1,618
| – | – | 0.03% | 142 |
|
|
2022
Q4 | $61.5K | Hold |
1,618
| – | – | 0.01% | 236 |
|
|
2022
Q3 | $41K | Sell |
1,618
-500
| -24% | -$13.9K | 0.01% | 267 |
|
|
2022
Q2 | $64K | Hold |
2,118
| – | – | 0.01% | 225 |
|
|
2022
Q1 | $69K | Hold |
2,118
| – | – | 0.01% | 218 |
|
|
2021
Q4 | $56K | Sell |
2,118
-565
| -21% | -$43.7K | 0.01% | 243 |
|
|
2021
Q3 | $270K | Hold |
2,683
| – | – | 0.06% | 117 |
|
|
2021
Q2 | $380K | Hold |
2,683
| – | – | 0.08% | 107 |
|
|
2021
Q1 | $267K | Sell |
2,683
-214
| -7% | -$25K | 0.06% | 120 |
|
|
2020
Q4 | $358K | Hold |
2,897
| – | – | 0.09% | 95 |
|
|
2020
Q3 | $282K | Buy |
2,897
+550
| +23% | +$68.7K | 0.08% | 103 |
|
|
2020
Q2 | $366K | Hold |
2,347
| – | – | 0.1% | 91 |
|
|
2020
Q1 | $339K | Buy |
2,347
+214
| +10% | +$41.3K | 0.11% | 84 |
|
|
2019
Q4 | $436K | Hold |
2,133
| – | – | 0.09% | 92 |
|
|
2019
Q3 | $171K | Hold |
2,133
| – | – | 0.04% | 122 |
|
|
2019
Q2 | $201K | Buy |
2,133
+565
| +36% | +$48.8K | 0.05% | 125 |
|
|
2019
Q1 | $134K | Hold |
1,568
| – | – | 0.03% | 147 |
|
|
2018
Q4 | $88K | Hold |
1,568
| – | – | 0.02% | 151 |
|
|
2018
Q3 | $128K | Buy |
+1,568
| New | +$111K | 0.03% | 150 |
|
Other funds holding RETA
Lee Financial's RETA Position: Q3 2023 in Review
Lee Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,618 shares — an estimated $165K sold.
Lee Financial first reported a position in RETA in Q3 2018 and held it in 20 quarters. The position peaked at $436K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Lee Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Lee Financial sold 1,618 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $165K.
- Lee Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 20 quarters.
- Lee Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $436K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Lee Financial's 13F filing for Q3 2023, filed 9 Nov 2023.